Mabapi le mofetše / kalafo / liteko tsa bongaka / lefu / mofets'e oa ka morao / kalafo
Kalafo Liteko tsa Kliniki ea Kankere ea Anal
Liteko tsa bongaka ke lithuto tsa lipatlisiso tse amang batho. Liteko tsa bongaka lethathamong lena ke tsa kalafo ea mofetše oa anal. Liteko tsohle tse lenaneng li tšehelitsoe ke NCI.
Tlhahisoleseling ea mantlha ea NCI mabapi le liteko tsa bongaka e hlalosa mefuta le mekhahlelo ea liteko le hore na li etsoa joang. Liteko tsa bongaka li sheba mekhoa e mecha ea ho thibela, ho lemoha kapa ho phekola mafu. U kanna ua batla ho nahana ka ho nka karolo tekong ea bongaka. Bua le ngaka ea hau bakeng sa thuso ho etsa qeto ea hore na e nepahetse ho uena.
Liteko 1-23 ea 23
Nivolumab kamora Phekolo ea Mekhoa e Kopaneng ea ho Phekola Bakuli ba nang le Kotsi e Phahameng ea II-IIIB ea Kankere
Teko ena ea liteko tsa bongaka ea karolo ea bobeli ea liteko tsa bongaka e bontša hore na nivolumab ka mor'a kalafo e kopaneng ea boits'oaro e sebetsa joang ho phekola bakuli ba nang le kotsi e kholo ea mofets'e oa II-IIIB anal. Immunotherapy e nang le lithibela-mafu tse monoclonal, joalo ka nivolumab, e ka thusa boits'ireletso ba mmele ho hlasela mofets'e, mme e ka sitisa bokhoni ba lisele tsa hlahala ho hola le ho hasana.
Sebaka: libaka tse 744
Nivolumab e nang le Ipilimumab kapa e se na eona ho Phekola bakuli ba nang le Refractory Metastatic Anal Canal Cancer
Karolo ea liteko tsa mohato ona oa bobeli e ithuta hore na nivolumab e na le kapa e se na ipilimumab e sebetsa ho phekola bakuli ba mofets'e oa anal canal o sa kang oa arabela kalafo ea pele (refractory) mme o hasane libakeng tse ling 'meleng (metastatic). Immunotherapy e nang le li-antibodies tsa monoclonal, joalo ka nivolumab le ipilimumab, e ka thusa sesole sa 'mele ho hlasela mofets'e, mme e ka sitisa bokhoni ba lisele tsa hlahala ho hola le ho hasana.
Sebaka: libaka tse 42
Nivolumab le Ipilimumab ha ba Phekola Bakuli ba nang le HIV ba amanang le ho khutla hape kapa ba nang le bothata ba Hodgkin Lymphoma kapa lihlahala tse tiileng tse nang le metastatic kapa tse ke keng tsa tlosoa ke ho buoa
Karolo ena ea liteko tsa karolo ea pele e hlahloba litla-morao le tekanyo e ntle ea nivolumab ha e fanoa ka ipilimumab ho phekola bakuli ba nang le vaerase ea ho itšireletsa mafung (HIV) e amanang le Hodgkin lymphoma ea khale e khutlileng kamora nako ea ntlafatso kapa e sa arabeleng kalafo, kapa lihlahala tse tiileng tse e hasane libakeng tse ling 'meleng kapa e ke ke ea tlosoa ka ho buuoa. Immunotherapy e nang le lithibela-mafu tse monoclonal, tse kang ipilimumab le nivolumab, e ka thusa sesole sa 'mele ho hlasela mofetše, mme e ka sitisa bokhoni ba lisele tsa hlahala ho hola le ho hasana. Ipilimumab ke antibody e sebetsang khahlanong le molek'hule e bitsoang cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 e laola karolo ea sesole sa hau sa 'mele ka ho e koala. Nivolumab ke mofuta oa antibody e ikhethileng bakeng sa lefu la motho le entsoeng 1 (PD-1), protheine e ikarabellang bakeng sa ho senya lisele tsa 'mele. Ho fana ka ipilimumab ka nivolumab ho ka sebetsa betere ho phekoleng bakuli ba nang le HIV ba amanang le Hodgkin lymphoma kapa lihlahala tse tiileng ha li bapisoa le ipilimumab le nivolumab feela.
Sebaka: libaka tse 28
Thuto ea XmAb®20717 ho Lihlooho tse nang le lihlahala tse tiileng tse tiileng tse tiileng
Ena ke Phase 1, tekanyetso e mengata, thuto e nyolohang ea litekanyetso ho hlalosa MTD / RD le regimen ea XmAb20717, ho hlalosa polokeho le mamello, ho lekola PK le boits'oaro ba mmele, le ho lekola pele ts'ebetso ea anti-tumor ea XmAb20717 ho lihlooho tse khethiloeng lihlahala tse tsoetseng pele tse tsoetseng pele.
Sebaka: libaka tse 15
Phuputso ea lipatlisiso tsa 'mele ea ho itšireletsa mafung ho etsa lipatlisiso tsa polokeho le katleho ea Nivolumab, le kalafo ea kopanyo ea Nivolumab ho lihlahala tse amanang le kokoana-hloko.
Morero oa phuputso ena ho batlisisa polokeho le katleho ea nivolumab, le kalafo ea motsoako oa nivolumab, ho phekola bakuli ba nang le lihlahala tse amanang le vaerase. Likokoana-hloko tse ling li tsebahala li bapala karolo ea ho theha hlahala le kholo. Phuputso ena e tla batlisisa litlamorao tsa meriana ea boithuto, ho bakuli ba nang le mefuta e latelang ea lihlahala: - Kankere ea Anal canal-Ha e sa ngolisa mofuta ona oa hlahala - Kankere ea mokokotlo - Epstein Barr Virus (EBV) mofets'e o nepahetseng oa kankere ea ka mpeng-Ha e sa ngolisa sena Mofuta oa hlahala - Kankere ea Merkel - Kankere ea Penile-Ha e sa ngolisa mofuta ona oa hlahala - Kankere ea Vaginal le ea vulvar-Ha e sa ngolisa mofuta ona oa hlahala - Cancer ea Nasopharyngeal - Ha e sa ngolisa mofuta ona oa hlahala - Kankere ea Hlooho le ea Nko - Ha e sa ngolisa mofuta ona oa hlahala
Sebaka: libaka tse 10
Boithuto ba Pembrolizumab (MK-3475) ho Barupeluoa ba nang le lihlahala tse matla tse tsoetseng pele (MK-3475-158 / KEYNOTE-158)
Phuputsong ena, bankakarolo ba nang le mefuta e mengata ea lihlahala tse tiileng tse tsoetseng pele (tse ke keng tsa qojoa le / kapa metastatic) tse tsoetseng pele kalafong e tloaelehileng ea kalafo ba tla phekoloa ka pembrolizumab.
Sebaka: libaka tse 8
Brachytherapy e Phahameng ea Moriana le Chemotherapy ho Phekola Bakuli ba nang le Phekolo ea Khafetsa kapa e Setseng ea Kankere e Phekolang e sa Sebetseng.
Karolo ena ea liteko tsa karolo ea pele e hlahloba litla-morao le tekanyetso e ntle ea brachytherapy e phahameng ha e fanoa hammoho le chemotherapy ho phekola bakuli ba nang le mofetše oa 'meleng kapa oa marao o khutlileng kapa o mpefetseng mme o ke keng oa phekoloa ka ho buuoa. Brachytherapy, eo hape e tsejoang e le kalafo ea radiation ea kahare, e sebelisa lisebelisoa tse ntšang mahlaseli a kotsi tse kenngoang ka kotlolloho kapa haufi le hlahala ho bolaea lisele tsa hlahala. Brachytherapy ea tekanyetso e phahameng (HDR) e sebelisa lisebelisoa tse nang le mahlaseli a kotsi ho fana ka leqhubu le phahameng la radiation ka nako e khuts'oane ho hlahala. E ka boela ea romela mahlaseli a fokolang ho lisele tse haufi tse phetseng hantle 'me ea fokotsa kotsi ea litla-morao. Lithethefatsi tse sebelisitsoeng chemotherapy, joalo ka capecitabine le fluorouracil, li sebetsa ka litsela tse fapaneng ho emisa kholo ea lisele tsa hlahala, ekaba ka ho bolaea lisele, ka ho li emisa ho arohana, kapa ka ho li emisa ho hasana.
Sebaka: libaka tse 6
Pembrolizumab ea ho Phekola Bakuli ba nang le Metastatic kapa sebakeng sa heno Kankere e Hlahlobang e ke keng ea Tlosoa ke ho Buoa
Karolo ea liteko tsa mohato ona oa bobeli e ithuta hore na pembrolizumab e sebetsa hantle hakae ho phekola bakuli ba mofets'e oa anal e nametseng libakeng tse ling 'meleng kapa e namileng ho tloha sebakeng sa eona sa pele sa kholo ho isa ho lisele tse haufi kapa li-lymph node mme e ke ke ea tlosoa ka ho buuoa. Immunotherapy e nang le lithibela-mafu tse monoclonal, joalo ka pembrolizumab, e ka thusa boits'ireletso ba mmele ho hlasela mofets'e, mme e ka sitisa bokhoni ba lisele tsa hlahala ho hola le ho hasana.
Sebaka: libaka tse 5
Phekolo ea ho phekola bakuli ba nang le Canal ea pele kapa Kankere ea Perianal le HIV e ntle
Karolo ena ea II ea liteko tsa liteko tsa ho alafa bakuli ba nang le kankere ea ka morao kapa kankere ea perianal e nyane ebile ha e so nametse kahare ho lisele le tšoaetso ea HIV. Ho buuoa sebakeng seo e ka ba kalafo e sireletsehileng e nang le litla-morao tse fokolang ho feta ho buuoa ho hoholo kapa radiation le chemotherapy.
Sebaka: libaka tse 5
Teko ea ho fumana le ho fuputsa lethal dose e sireletsehileng ea ntho e ncha (BI 754091) bakeng sa bakuli ba nang le lihlahala tse tiileng.
Morero oa mantlha oa karolo ea keketseho ea tekanyetso ke ho tseba polokeho le mamello, le ho fumana Maximum Tolerated Dose le / kapa Khothaletso ea Phase 2 Dose (RP2D) ea BI 754091 motheong oa bakuli ba nang le moeli oa tekanyetso. toxicities (DLTs) ho bakuli ba nang le malignancies a tiileng a tsoetseng pele a khethiloeng. Polokeho le mamello li tla hlahlojoa ka ho lekola ho ba teng ha liketsahalo tse mpe (AEs), AEs tse tebileng (SAE), le maemo a sa tloaelehang a parameter ea laboratori, hammoho le liphetoho lipontšong tsa bohlokoa. Morero oa bobeli ke boikemisetso ba boemo ba PK ba BI 754091 kamora tekanyetso e le 'ngoe le e mengata ea BI 754091, le tekolo ea pele ea ts'ebetso ea likokoana-hloko. Karolong ea tekolo ea tekanyetso, sepheo sa mantlha ke ho lekola ts'ireletseho, katleho, boemo ba PK,
Sebaka: libaka tse 3
Stereotactic Radiosurgery ho Phekola Bakuli ba nang le Mafu a Oligometastatic
Teko ena ea mohato oa II e ithuta hore na radiosurgery ea stereotactic e sebetsa hantle joang ho phekoleng bakuli ba mofets'e ba hasaneng libakeng tse 5 kapa tse fokolang 'meleng mme e kenyelletsa litho tsa 3 kapa tse fokolang (lefu la oligometastatic). Stereotactic radiosurgery, eo hape e tsejoang ka hore ke stereotactic radiation therapy, ke kalafo e ikhethang ea radiation e fanang ka leqhubu le le leng, le phahameng la radiation ka kotloloho ho hlahala mme e ka bolaea lisele tse ngata tsa hlahala mme e baka tšenyo e nyane ho lisele tse tloaelehileng.
Sebaka: libaka tse 3
A Study of INCMGA00012 in Squamous Carcinoma of the Can Canal following Platinum-Based Chemotherapy (POD1UM-202)
Morero oa phuputso ena ke ho lekola ho sebetsa ha INCMGA00012 ho bankakarolo ba nang le carcinoma e tsoetseng pele ea lehae kapa ea metastatic squamous ea canal (SCAC) ba tsoetseng pele kamora chemotherapy e thehiloeng ho platinamo.
Sebaka: libaka tse 4
Artesunate ho Phekola Bakuli ba nang le Neoplasia e Phahameng ea Kereiti ea Anal Anal Intraepithelial
Karolo ena ea liteko tsa karolo ena ea pele e hlahloba litla-morao le tekanyo e ntle ea artesunate ho phekola bakuli ba nang le boemo bo phahameng ba "anal intraepithelial neoplasia". Anal intraepithelial neoplasia ke lisele tse sa tsitsang tse ka 'nang tsa e-ba kankere nakong e tlang. Boholo ba liphetoho tse lebisang kankere li bakoa ke papillomavirus ea motho (HPV). Artesunate e ka bolaea lisele tse tšoaelitsoeng ke HPV.
Sebaka: libaka tse 2
Phuputso ea LY3434172, PD-1 le PD-L1 Bispecific Antibody, ho Kankere e tsoetseng pele
Morero oa mantlha oa phuputso ena ke ho lekola polokeho le mamello ea moriana oa thuto LY3434172, lesole la mmele la PD-1 / PD-L1 bispecific, ho bankakarolo ba nang le lihlahala tse tsoetseng pele tse tiileng.
Sebaka: Setsi sa Kankere sa MD Anderson, Houston, Texas
SL-279252 (PD1-Fc-OX40L) ho Lihlooho tse nang le lihlahala tse matla tse tsoetseng pele kapa li-lymphomas
Ena ke Phase 1 ea pele ho li-label tsa batho, tse bulehileng, tse nang le libaka tse ngata, ho nyoloha ha litekanyetso le thuto ea katoloso ea litekanyetso ho lekola polokeho, mamello, PK, ts'ebetso ea anti-tumor le litlamorao tsa SL-279252 lithutong tse nang le lihlahala tse tsoetseng pele kapa li-lymphomas. .
Sebaka: Setsi sa Kankere sa MD Anderson, Houston, Texas
LET-IMPT le Chemotherapy e Tloaelehileng ea ho Phekola Bakuli ba nang le Kankere ea Cell-squamous Cell e sa tsoa fumanoa
Teko ea mohato ona oa II e ithuta litla-morao tsa LET-IMPT le chemotherapy e tloaelehileng, le hore na li sebetsa hantle hakae ho phekola bakuli ba nang le mofetše oa sele e sa tsoa fumanoa oa I-III anal canal squamous cell. LET-IMPT ke mofuta oa kalafo ea radiation e sebelisang "maballo" a matla a matla a matla ho "penta" lethal dose mahlaseling mme e ka thusa ho bolaea lisele tsa hlahala le ho nyenyefatsa lihlahala. Ho fana ka LET-IMPT le chemotherapy e tloaelehileng ho ka sebetsa hantle ho phekoleng bakuli ba nang le mofetše oa sele oa squamous cell.
Sebaka: Setsi sa Kankere sa MD Anderson, Houston, Texas
VGX-3100 le Electroporation ho Phekola Bakuli ba nang le HIV le Positive High-grade Anal Diso
Mokhahlelo ona oa bobeli oa liteko o ithuta hore na papillomavirus (HPV) deoxyribonucleic acid (DNA) ea motho e entša kalafo ea kalafo ea plasmids VGX-3100 (VGX-3100) le mosebetsi oa motlakase ho phekola bakuli ba nang le liso tse phahameng tsa tšoaetso ea immunodeficiency virus (HIV). Meento e entsoeng ka DNA e ka thusa 'mele ho aha tšebetso e ntle ea boits'ireletso ea mmele ho bolaea lisele tsa hlahala. Motlakase o thusa masoba maseleng a 'mele oa hau ho noa moriana ho matlafatsa karabelo ea sesole sa hau sa' mele. Ho fana ka VGX-3100 le ho kopanya motlakase ho ka sebetsa hantle ho phekola bakuli ba nang le liso tsa anal tsa boemo bo holimo.
Sebaka: libaka tse 2
DNA Plasmid-encoding Interleukin-12 / HPV DNA Plasmids Therapeutic Vaccine INO-3112 le Durvalumab ea ho Phekola Bakuli ba nang le Kankere e Kopaneng ea Metapatic Human Metillatic Papillomavirus.
Karolo ena ea liteko tsa karolo ea II e ithuta hore na deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12 / human papillomavirus (HPV) DNA plasmids ea kalafo ea ente INO-3112 le durvalumab e sebetsa ho phekola bakuli ba nang le mofetše o amanang le papillomavirus oa batho o khutlileng kapa o hasaneng ho tse ling. dibaka mmeleng. Meento e entsoeng ka vaerase e fetotsoeng ke liphatsa tsa lefutso e ka thusa 'mele ho aha boits'ireletso bo matla ba mmele ho bolaea lisele tsa hlahala. Immunotherapy e nang le lithibela-mafu tse monoclonal, joalo ka durvalumab, e ka thusa boits'ireletso ba mmele ho hlasela mofets'e, mme e ka sitisa bokhoni ba lisele tsa hlahala ho hola le ho hasana. Ho fana ka DNA plasmid-encoding interleukin-12 / HPV DNA plasmids ente ea kalafo ea kalafo INO-3112 le durvalumab li ka sebetsa hantle ho phekola bakuli ba nang le mofetše oa papillomavirus oa motho.
Sebaka: Setsi sa Kankere sa MD Anderson, Houston, Texas
M7824 ho Lihlooho le HPV Associated Malignancies
Ka morao: United States, selemo se seng le se seng ho na le linyeoe tse fetang 30,000 tsa mofets'e o amanang le papillomavirus (HPV). Tse ling tsa mofetše ona hangata ha li phekolehe ebile ha li ntlafatsoe ke kalafo e tloaelehileng. Bafuputsi ba batla ho bona hore na sethethefatsi se secha M7824, se shebileng le ho thiba tsela e thibelang sesole sa 'mele ho loants'a mofets'e se ka fokotsa lihlahala ho batho ba nang le mofetše oa HPV. Morero: Ho bona hore na moriana M7824 o baka lihlahala hore li fokotsehe. Ho tsoaneleha: Batho ba baholo ba lilemo li 18 le ho feta ba nang le mofetše o amanang le tšoaetso ea HPV. Moralo: Barupeluoa ba tla hlahlojoa ka nalane ea bongaka le tlhahlobo ea 'mele. Ba tla lekola matšoao a bona le hore na ba etsa mesebetsi e tloaelehileng joang. Ba tla ba le lisepa tsa 'mele. Ba tla fana ka mehlala ea mali le moroto. Ba tla nkuoa sampole ea lisele tsa bona tsa hlahala haeba e le 'ngoe e sa fumanehe. Barupeluoa ba tla ba le electrocardiogram ho lekola lipelo tsa bona. Ebe ba tla fumana moriana oa boithuto ka phaephe e tšesaane e mothapong oa letsoho. Barupeluoa ba tla fumana sethethefatsi sena libeke tse ling le tse ling tse 2 ka makhetlo a 26 (selemo se le seng). Ena ke thupelo e 1. Kamora thupelo, bankakarolo ba tla beoa leihlo empa ba ke ke ba noa moriana oa boithuto. Haeba boemo ba bona bo mpefala, ba tla qala thupelo e 'ngoe ka sethethefatsi. Ts'ebetso ena e ka phetoa makhetlo a mangata kamoo ho hlokahalang. Kalafo e tla emisa haeba bankakarolo ba na le litla-morao tse mpe kapa sethethefatsi se emisa ho sebetsa. Nakong eohle ea boithuto, bankakarolo ba tla pheta tse ling kapa liteko tsohle tsa tlhahlobo. Kamora hore barupeluoa ba khaotse ho noa moriana, ba tla ba le ketelo e latelang ebe ba pheta liteko tse ling tsa tlhahlobo. Ba tla fumana mehala ea ho latellana nako le nako. ... Ebe ba tla fumana moriana oa boithuto ka phaephe e tšesaane e mothapong oa letsoho. Barupeluoa ba tla fumana sethethefatsi sena libeke tse ling le tse ling tse 2 ka makhetlo a 26 (selemo se le seng). Ena ke thupelo e 1. Kamora thupelo, bankakarolo ba tla beoa leihlo empa ba ke ke ba noa moriana oa boithuto. Haeba boemo ba bona bo mpefala, ba tla qala thupelo e 'ngoe ka sethethefatsi. Ts'ebetso ena e ka phetoa makhetlo a mangata kamoo ho hlokahalang. Kalafo e tla emisa haeba bankakarolo ba na le litla-morao tse mpe kapa sethethefatsi se emisa ho sebetsa. Nakong eohle ea boithuto, bankakarolo ba tla pheta tse ling kapa liteko tsohle tsa tlhahlobo. Kamora hore barupeluoa ba khaotse ho noa moriana, ba tla ba le ketelo e latelang ebe ba pheta liteko tse ling tsa tlhahlobo. Ba tla fumana mehala ea ho latellana nako le nako. ... Ebe ba tla fumana moriana oa boithuto ka phaephe e tšesaane e mothapong oa letsoho. Barupeluoa ba tla fumana sethethefatsi sena libeke tse ling le tse ling tse 2 ka makhetlo a 26 (selemo se le seng). Ena ke thupelo e 1. Kamora thupelo, bankakarolo ba tla beoa leihlo empa ba ke ke ba noa moriana oa boithuto. Haeba boemo ba bona bo mpefala, ba tla qala thupelo e 'ngoe ka sethethefatsi. Ts'ebetso ena e ka phetoa makhetlo a mangata kamoo ho hlokahalang. Kalafo e tla emisa haeba bankakarolo ba na le litla-morao tse mpe kapa sethethefatsi se emisa ho sebetsa. Nakong eohle ea boithuto, bankakarolo ba tla pheta tse ling kapa liteko tsohle tsa tlhahlobo. Kamora hore barupeluoa ba khaotse ho noa moriana, ba tla ba le ketelo e latelang ebe ba pheta liteko tse ling tsa tlhahlobo. Ba tla fumana mehala ea ho latellana nako le nako. ... bankakarolo ba tla beoa leihlo empa ba ke ke ba noa moriana oa boithuto. Haeba boemo ba bona bo mpefala, ba tla qala thupelo e 'ngoe ka sethethefatsi. Ts'ebetso ena e ka phetoa makhetlo a mangata kamoo ho hlokahalang. Kalafo e tla emisa haeba bankakarolo ba na le litla-morao tse mpe kapa sethethefatsi se emisa ho sebetsa. Nakong eohle ea boithuto, bankakarolo ba tla pheta tse ling kapa liteko tsohle tsa tlhahlobo. Kamora hore barupeluoa ba khaotse ho noa moriana, ba tla ba le ketelo e latelang ebe ba pheta liteko tse ling tsa tlhahlobo. Ba tla fumana mehala ea ho latellana nako le nako. ... bankakarolo ba tla beoa leihlo empa ba ke ke ba noa moriana oa boithuto. Haeba boemo ba bona bo mpefala, ba tla qala thupelo e 'ngoe ka sethethefatsi. Ts'ebetso ena e ka phetoa makhetlo a mangata kamoo ho hlokahalang. Kalafo e tla emisa haeba bankakarolo ba na le litla-morao tse mpe kapa sethethefatsi se emisa ho sebetsa. Nakong eohle ea boithuto, bankakarolo ba tla pheta tse ling kapa liteko tsohle tsa tlhahlobo. Kamora hore barupeluoa ba khaotse ho noa moriana, ba tla ba le ketelo e latelang ebe ba pheta liteko tse ling tsa tlhahlobo. Ba tla fumana mehala ea ho latellana nako le nako. ... Kamora hore barupeluoa ba khaotse ho noa moriana, ba tla ba le ketelo e latelang ebe ba pheta liteko tse ling tsa tlhahlobo. Ba tla fumana mehala ea ho latellana nako le nako. ... Kamora hore barupeluoa ba khaotse ho noa moriana, ba tla ba le ketelo e latelang ebe ba pheta liteko tse ling tsa tlhahlobo. Ba tla fumana mehala ea ho latellana nako le nako. ...
Sebaka: Mekhatlo ea Naha ea Setsi sa Bongaka sa Bophelo, Bethesda, Maryland
MnSOD Mimetic BMX-001 ho Phekola Bakuli ba nang le Kankere ea Phekolo ea Phekolo ea Mahlaseli a kotsi le Chemotherapy
Karolo ena ea liteko tsa karolo ea pele ea liteko tsa MnSOD BMX-001 ho fokotsa litlamorao ho bakuli ba nang le mofetše oa anal ba alafshoang ke radiation le chemotherapy. Lithethefatsi tsa Chemoprotective, joalo ka BMX-001, li ka sireletsa lisele tse tloaelehileng litlamorao tsa chemotherapy ha li ntse li matlafatsa polao ea hlahala.
Sebaka: Setsi sa Bongaka sa Univesithi ea Nebraska, Omaha, Nebraska
Atezolizumab le Bevacizumab ho phekola bakuli ba nang le lihlahala tse sa tloaelehang
Karolo ena ea liteko tsa karolo ea II e ithuta hore na atezolizumab le bevacizumab li sebetsa joang ho phekola bakuli ba nang le lihlahala tse sa tloaelehang. Immunotherapy e nang le lithibela-mafu tse monoclonal, joalo ka atezolizumab le bevacizumab, e ka thusa sesole sa 'mele ho hlasela mofetše, mme e ka sitisa bokhoni ba lisele tsa hlahala ho hola le ho hasana.
Sebaka: Setsi sa Kankere sa MD Anderson, Houston, Texas
Therapy ea Vaccine le Cyclophosphamide ho Phekola Bakuli ba nang le HLA-A * 02 Positive Relapsed, Refractory, or Metastatic HPV16-Related Oropharyngeal, Cervical, kapa Anal Cancer
Karolo ena ea liteko tsa litla-morao tsa Ib / II le tekanyetso e ntle ea ente ea HPV16-E711-19 nanomer DPX-E7 le ho bona hore na e sebetsa hantle ha e fanoa le cyclophosphamide ho phekola bakuli ba nang le tšoaetso ea HLA-A * 02, papillomavirus ea motho 16 ( HPV16) e amanang le oropharyngeal, mokokotlo, kapa mofetše oa anal o khutlileng, ha o arabele kalafo, kapa o nametse likarolong tse ling tsa 'mele. Meento e entsoeng ka vaerase e fetotsoeng ke liphatsa tsa lefutso e ka thusa 'mele ho aha boits'ireletso bo matla ba mmele ho bolaea lisele tsa hlahala. Lithethefatsi tse sebelisitsoeng chemotherapy, joalo ka cyclophosphamide, li sebetsa ka litsela tse fapaneng ho emisa kholo ea lisele tsa hlahala, ekaba ka ho bolaea lisele, ka ho li emisa ho arohana, kapa ka ho li thibela ho hasana. Ho fa ente ea HPV16-E711-19 nanomer DPX-E7 hammoho le cyclophosphamide ho ka sebetsa hantle ho phekola bakuli ba nang le oropharyngeal e amanang le HPV16,
Sebaka: Dana-Farber Cancer Institute, Boston, Massachusetts
Nivolumab le Ipilimumab ho phekola bakuli ba nang le lihlahala tse sa tloaelehang
Karolo ea II ea liteko tsa liteko tsa nivolumab le ipilimumab ho phekola bakuli ba nang le lihlahala tse sa tloaelehang. Immunotherapy e nang le lithibela-mafu tse monoclonal, joalo ka nivolumab le ipilimumab, e ka thusa sesole sa 'mele ho hlasela mofetše, mme e ka sitisa bokhoni ba lisele tsa hlahala ho hola le ho hasana. Teko ena e ngolisa barupeluoa bakeng sa lihlopha tse latelang tse ipapisitseng le maemo: 1. Lihlahala tsa epithelial tsa masapo a nko, libe, nasopharynx: A) Squamous cell carcinoma e nang le mefuta e meng ea masapo, li-sinus, le nasopharynx le trachea (ntle le laryngeal, nasopharyngeal cancer [NPC] , le squamous cell carcinoma ea hlooho le molala [SCCHN]) B) Adenocarcinoma le mefuta e meng ea masapo, lisosa le nasopharynx (e koetsoe ho fihlela 07/27/2018) 2. Lihlahala tsa epithelial tsa litšoelesa tse kholo tsa salivary (li koetsoe ho fihlela ho 03) / 20/2018) 3. Mofuta oa tšoelesa ea "salivary" ea hlooho le molala, molomo, 'metso, mala, trachea le matšoafo, sefuba le sebaka se seng (se koetsoeng ho fihlela se le seng) 4. Kankere e sa khetholloeng ea pampiri ea meno (GI) 5. Adenocarcinoma e nang le mefuta e meng ea mala a manyane (e koetsoe ho fihlela e le teng) 05/10/2018) 6. Squamous cell carcinoma e nang le mefuta e fapaneng ea pampitšana ea GI (mala a manyane, mala, rectum, manyeme) (e koetsoe ho fihlela 10/17/2018) 7. Fibromixoma le grade ea mucinous adenocarcinoma (pseudomixoma peritonei) ea sehlomathiso le ovary (e koetsoe ho fihlela ka la 03/20/2018) 8. Lihlahala tse sa tloaelehang tsa pancreatic tse kenyeletsang acinar cell carcinoma, mucinous cystadenocarcinoma kapa serous cystadenocarcinoma. Pancreatic adenocarcinoma ha e tšoanelehe 9. Intrahepatic cholangiocarcinoma (e koetsoe ho fihlela ka la 03/20/2018) 10. Extrahepatic cholangiocarcinoma le li-tumor tsa bile (tse koetsoeng ho fihlela ka la 03/20/2018) 11. Sarcomatoid carcinoma ea matšoafo 12. Bronchoalveolar carcinoma lung. Boemo bona hona joale bo boetse bo bitsoa adenocarcinoma in situ, adenocarcinoma e hlaselang hanyane, adenocarcinoma e nang le lepidic, kapa adinocarcinoma e hlaselang 13. A lihlahala tse sa sebetseng tsa ovary: A) Lefu la sele la germ la ovary B) hlahala e tsoakiloeng ea Mullerian le adenosarcoma (e koetsoe) ho hola 03/30/2018) 14. Lefu la trophoblastic: A) Choriocarcinoma (e koetsoe ho fihlela ka la 04/15/2019) 15. Transitional cell carcinoma ntle le ea renal, pelvis, ureter kapa senya (e koetsoe ho fihlela 04 / 15/2019) 16. Tumelo ea sele ea li-testes le li-tumor tsa extragonadal: Lihlahala tsa Apocrine / extramammary Boloetse ba Paget 40. Peritoneal mesothelioma 41. Basal cell carcinoma 42. Hlakola mofetše oa sele 43. Esthenioneuroblastoma 44. Endometrial carcinosarcoma (lihlahala tse tsoakaneng tsa Mullerian) (e koetsoe ho fihlela li bokellana) 45. Hlakola mofetše oa sele oa endometrium ea sele. mofets'e oa mahe a bomme 47. Lefu la Gestational trophoblastic (GTD) 48. Kankere ea 'mele ea' mele 49. Lisele tse nyane tsa carcinoma tsa ovary, mofuta oa hypercalcemic 50. PD-L1 li holisa lihlahala 51. Angiosarcoma 52. Neuroendocrine carcinoma ea maemo a holimo (hlahala ea pancreatic neuroendocrine [PNET] e lokela ho ngolisoa ho Cohort 22; prostatic neuroendocrine carcinomas e lokela ho ngolisoa ho Cohort 53). Kankere ea matšoafo ea lisele tse nyane ha e tšoanelehe 53. Kankere Hlakola kankere ea mokokotlo oa sele 43. Esthenioneuroblastoma 44. Endometrial carcinosarcoma (lihlahala tse tsoakiloeng tse tsoakaneng tsa Mullerian) (li koetsoe ho fihlela li bokellana) 45. Hlakola mofetše oa sele oa endometrium oa sele. 46. Hlakola mofets'e oa cell ovarian 47. Gestational trophoblastic disease (GTD) 48. Kankere ea gallbladder 49. Nyane cell carcinoma ea ovary, mofuta oa hypercalcemic 50. PD-L1 li eketsehile lihlahala 51. Angiosarcoma 52. Neuroendocrine carcinoma e phahameng (pancreatic neuroendocrine tumor [PNET] e lokela ho ngolisoa ho Cohort 22; prostatic neuroendocrine carcinomas e lokela ho ngolisoa ho Cohort 53). Kankere ea matšoafo ea lisele tse nyane ha e tšoanelehe 53. Kankere Hlakola kankere ea mokokotlo oa sele 43. Esthenioneuroblastoma 44. Endometrial carcinosarcoma (lihlahala tse tsoakiloeng tse tsoakaneng tsa Mullerian) (li koetsoe ho fihlela li bokellana) 45. Hlakola mofetše oa sele oa endometrium oa sele. 46. Hlakola mofets'e oa cell ovarian 47. Gestational trophoblastic disease (GTD) 48. Kankere ea gallbladder 49. Nyane cell carcinoma ea ovary, mofuta oa hypercalcemic 50. PD-L1 li eketsehile lihlahala 51. Angiosarcoma 52. Neuroendocrine carcinoma e phahameng (pancreatic neuroendocrine tumor [PNET] e lokela ho ngolisoa ho Cohort 22; prostatic neuroendocrine carcinomas e lokela ho ngolisoa ho Cohort 53). Kankere ea matšoafo ea lisele tse nyane ha e tšoanelehe 53. Kankere Hlakola mofetše oa lisele tsa mahe a bomme 47. Lefu la Gestational trophoblastic (GTD) 48. Kankere ea 'meleng ea sethoathoa 49. Cellcinoma e nyane ea ovary, mofuta oa hypercalcemic 50. PD-L1 e holisa lihlahala 51. Angiosarcoma 52. Neuroendocrine carcinoma e phahameng (hlahala ea pancreatic neuroendocrine [PNET ] o lokela ho ngolisoa ho Cohort 22; prostatic neuroendocrine carcinomas e lokela ho ngolisoa ho Cohort 53). Kankere ea matšoafo ea lisele tse nyane ha e tšoanelehe 53. Kankere Hlakola mofetše oa lisele tsa mahe a bomme 47. Lefu la Gestational trophoblastic (GTD) 48. Kankere ea 'meleng ea sethoathoa 49. Cellcinoma e nyane ea ovary, mofuta oa hypercalcemic 50. PD-L1 e holisa lihlahala 51. Angiosarcoma 52. Neuroendocrine carcinoma e phahameng (hlahala ea pancreatic neuroendocrine [PNET ] o lokela ho ngolisoa ho Cohort 22; prostatic neuroendocrine carcinomas e lokela ho ngolisoa ho Cohort 53). Kankere ea matšoafo ea lisele tse nyane ha e tšoanelehe 53. Kankere Prostatic neuroendocrine carcinomas e lokela ho ngolisoa ho Cohort 53). Kankere ea matšoafo ea lisele tse nyane ha e tšoanelehe 53. Kankere Prostatic neuroendocrine carcinomas e lokela ho ngolisoa ho Cohort 53). Kankere ea matšoafo ea lisele tse nyane ha e tšoanelehe 53. Kankere
Sebaka: libaka tse 878
